169 related articles for article (PubMed ID: 35847495)
41. Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors.
Chen D; Li G; Ji C; Lu Q; Qi Y; Tang C; Xiong J; Hu J; Yasar FBA; Zhang Y; Hoon DSB; Yao Y; Zhou L
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457124
[TBL] [Abstract][Full Text] [Related]
42. Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition.
Mao W; Ghasemzadeh A; Freeman ZT; Obradovic A; Chaimowitz MG; Nirschl TR; McKiernan E; Yegnasubramanian S; Drake CG
J Immunother Cancer; 2019 Oct; 7(1):277. PubMed ID: 31653272
[TBL] [Abstract][Full Text] [Related]
43. Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein BRD4 inhibitor (+)-JQ1 in cancer cells.
Sui S; Zhang J; Xu S; Wang Q; Wang P; Pang D
Cell Death Dis; 2019 Apr; 10(5):331. PubMed ID: 30988278
[TBL] [Abstract][Full Text] [Related]
44. Combination of Chidamide-Mediated Epigenetic Modulation with Immunotherapy: Boosting Tumor Immunogenicity and Response to PD-1/PD-L1 Blockade.
Tu K; Yu Y; Wang Y; Yang T; Hu Q; Qin X; Tu J; Yang C; Kong L; Zhang Z
ACS Appl Mater Interfaces; 2021 Aug; 13(33):39003-39017. PubMed ID: 34433253
[TBL] [Abstract][Full Text] [Related]
45. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
Wang Z; Wu X
Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
[TBL] [Abstract][Full Text] [Related]
46. EZH2 Inhibitors Suppress Colorectal Cancer by Regulating Macrophage Polarization in the Tumor Microenvironment.
Li C; Song J; Guo Z; Gong Y; Zhang T; Huang J; Cheng R; Yu X; Li Y; Chen L; Ma X; Sun Y; Wang Y; Xue L
Front Immunol; 2022; 13():857808. PubMed ID: 35432300
[TBL] [Abstract][Full Text] [Related]
47. Dichloroacetate improves immune dysfunction caused by tumor-secreted lactic acid and increases antitumor immunoreactivity.
Ohashi T; Akazawa T; Aoki M; Kuze B; Mizuta K; Ito Y; Inoue N
Int J Cancer; 2013 Sep; 133(5):1107-18. PubMed ID: 23420584
[TBL] [Abstract][Full Text] [Related]
48. Crosstalk between IL-15Rα
Zhang W; Zhang Q; Yang N; Shi Q; Su H; Lin T; He Z; Wang W; Guo H; Shen P
Cancer Commun (Lond); 2022 Jun; 42(6):536-557. PubMed ID: 35615815
[TBL] [Abstract][Full Text] [Related]
49. Histone Acetylation Regulator-Mediated Acetylation Patterns Define Tumor Malignant Pathways and Tumor Microenvironment in Hepatocellular Carcinoma.
Xu Y; Liao W; Luo Q; Yang D; Pan M
Front Immunol; 2022; 13():761046. PubMed ID: 35145517
[TBL] [Abstract][Full Text] [Related]
50. Biomimetic nanoparticles directly remodel immunosuppressive microenvironment for boosting glioblastoma immunotherapy.
Wang T; Zhang H; Qiu W; Han Y; Liu H; Li Z
Bioact Mater; 2022 Oct; 16():418-432. PubMed ID: 35386309
[TBL] [Abstract][Full Text] [Related]
51. Ritonavir acts synergistically with panobinostat to enhance histone acetylation and inhibit renal cancer growth.
Sato A; Asano T; Isono M; Ito K; Asano T
Mol Clin Oncol; 2014 Nov; 2(6):1016-1022. PubMed ID: 25279191
[TBL] [Abstract][Full Text] [Related]
52. Targeted Glucose or Glutamine Metabolic Therapy Combined With PD-1/PD-L1 Checkpoint Blockade Immunotherapy for the Treatment of Tumors - Mechanisms and Strategies.
Ma G; Li C; Zhang Z; Liang Y; Liang Z; Chen Y; Wang L; Li D; Zeng M; Shan W; Niu H
Front Oncol; 2021; 11():697894. PubMed ID: 34327138
[TBL] [Abstract][Full Text] [Related]
53. Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression.
Saleh R; Toor SM; Sasidharan Nair V; Elkord E
Front Immunol; 2020; 11():1469. PubMed ID: 32760400
[TBL] [Abstract][Full Text] [Related]
54. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
[TBL] [Abstract][Full Text] [Related]
55. Immune checkpoint therapy in liver cancer.
Xu F; Jin T; Zhu Y; Dai C
J Exp Clin Cancer Res; 2018 May; 37(1):110. PubMed ID: 29843754
[TBL] [Abstract][Full Text] [Related]
56. CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment
Park S; Oh JH; Park DJ; Zhang H; Noh M; Kim Y; Kim YS; Kim H; Kim YM; Ha SJ; Kwon YG
Front Immunol; 2020; 11():620166. PubMed ID: 33584714
[TBL] [Abstract][Full Text] [Related]
57. A Systematic Review of the Tumor-Infiltrating CD8
Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
Front Immunol; 2021; 12():734956. PubMed ID: 34603316
[TBL] [Abstract][Full Text] [Related]
58. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.
Knudson KM; Hicks KC; Alter S; Schlom J; Gameiro SR
J Immunother Cancer; 2019 Mar; 7(1):82. PubMed ID: 30898149
[TBL] [Abstract][Full Text] [Related]
59. Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronate.
Rajan R; Sabnani MK; Mavinkurve V; Shmeeda H; Mansouri H; Bonkoungou S; Le AD; Wood LM; Gabizon AA; La-Beck NM
J Control Release; 2018 Feb; 271():139-148. PubMed ID: 29277680
[TBL] [Abstract][Full Text] [Related]
60. eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma.
Chen X; Wang K; Jiang S; Sun H; Che X; Zhang M; He J; Wen Y; Liao M; Li X; Zhou X; Song J; Ren X; Yi W; Yang J; Chen X; Yin M; Cheng Y
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35347072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
